Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | ENPP3 | O14638 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841213 | 1.00 | KDR (0.48) | KDRENPP3MAPTKDM4EPDE5A | |
| SCHEMBL1832096 | 0.83 | KDR (0.48) | KDRENPP3MAPTKDM4EPDE5A | |
| SCHEMBL9988170 | 0.83 | KDR (0.48) | KDRENPP3MAPTKDM4EPDE5A | |
| SCHEMBL1835319 | 0.78 | KDR (0.65) | KDRMAPTPOLB | |
| SCHEMBL15291820 | 0.78 | KDR (0.50) | KDRENPP3MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1832652 | 0.77 | KDR (0.55) | KDRENPP3MAPTKDM4EPDE5A | |
| SCHEMBL1838211 | 0.76 | KDR (0.48) | KDRENPP3MAPTALDH1A1LMNA | |
| SCHEMBL1841510 | 0.75 | KDR (0.45) | KDRENPP3MAPTLMNAAURKA | |
| SCHEMBL1832537 | 0.74 | KDR (0.48) | KDRENPP3MAPTKDM4EPDE5A | |
| SCHEMBL1832534 | 0.74 | KDR (0.48) | KDRENPP3MAPTKDM4EPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321298-B1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-10-02 | — | — | EP | claimed |
| US-20110301162-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-12-08 | — | — | US | claimed |
| EP-2321298-A2 | AURORA KINASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010017240-A2 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-11 | — | — | WO | claimed |
| EP-2321298-B1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20110301162-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2321298-A2 | AURORA KINASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010017240-A2 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301162-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AURKC, AURKA, CDK1 | KDR 538/4885ENPP3 1367/4885MAPT 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.